ArticleOncotarget2015

A set of defined oncogenic mutation alleles seems to better predict the response to cetuximab in CRC patient-derived xenograft than KRAS 12/13 mutations.

Dawei Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.